id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-4769	Di Brizzi, Eugenia Veronica; Caccavale, Stefano; Di Caprio, Roberta; Cusano, Francesco; De Pasquale , Rocco; Falcomatà, Valeria; Foti, Caterina; Giofrè, Claudia; Gubinelli, Emanuela; Mazzocchetti, Giampiero ; Nicolini, Massimiliano; Palazzo, Giovanni; Pescitelli, Leonardo ; Puca, Rosa Valentina; Sarno, Oriele; Balato, Anna 	Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?	2024	8	.pdf	application/pdf	4979	367	56	Pescara, Italy 9 Carlo Urbani Hospital, Jesi, Ancona, Italy 10 Dermatology, Ospedale distrettuale “A. Lo Dico”, Matera, Italy 11 Unit of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy 12 Department of Dermatology and Dermosurgery, AOSG San Giuseppe Moscati, 83100 Avellino, Italy Key words: Tildrakizumab 200 mg, Psoriasis, Anti-IL23, Psoriasis treatment, Obesity, Dose escalation Citation: Di Brizzi EV, Caccavale S, Di Caprio R, et al. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.	cache/dpc-4769.pdf	txt/dpc-4769.txt